Home › Research › Treatments
Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis
Ji H, Yang Y, Wu X, Bao E.. Frontiers in neuroinformatics, 2026-10-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Although clinical trials have demonstrated its favorable safety profile, real-world studies are crucial for identifying rare adverse events (AEs) and evaluating post-marketing safety. Results The single-center prospective study enrolled a total of 91 patients. Furthermore, FAERS analysis revealed a potential safety signal for cerebral infarction. Conclusion In this single-center prospective observational study, lecanemab demonstrated a generally favorable safety profile.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ji, H., Yang, Y., Wu, X., & Bao, E. (2026). Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis. Frontiers in neuroinformatics. https://doi.org/10.3389/fninf.2026.1977226
Vancouver
Ji H, Yang Y, Wu X, Bao E. Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis. Frontiers in neuroinformatics. 2026. doi:10.3389/fninf.2026.1977226. PMID: 42890205.
BibTeX
@article{ji2026-42890205,
author = {Ji, H. and Yang, Y. and Wu, X. and Bao, E.},
title = {{Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis}},
journal = {Frontiers in neuroinformatics},
year = {2026},
doi = {10.3389/fninf.2026.1977226},
pmid = {42890205},
url = {https://doi.org/10.3389/fninf.2026.1977226}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Although clinical trials have demonstrated its favorable safety profile, real-world studies are crucial for identifying rare adverse events (AEs) and evaluating post-marketing safety.
- Results The single-center prospective study enrolled a total of 91 patients.
- Furthermore, FAERS analysis revealed a potential safety signal for cerebral infarction.
- Conclusion In this single-center prospective observational study, lecanemab demonstrated a generally favorable safety profile.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants393
- Effect size45.65%
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 34 of the 58 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in neuroinformatics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 393 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42890205) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 34 of the 58 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “supported”
3 studies in the library carry the topic tag “supported”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.